Abstract:
Drugs that target the programmed cell death-1 (PD-1) receptor have shown promising antitumor activity in clinical trials, but it is not clear whether expression of the ligand PD-L1 is a biomarker for response. Increasingly, researchers say that PD-L1 expression is just one of many variables that may affect response to PD-1 blockade.
